Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
APOL1 encodes a secreted high density lipoprotein which binds to apolipoprotein A-I. Additionally we are shipping APOL1 Kits (25) and APOL1 Proteins (5) and many more products for this protein.
Showing 10 out of 119 products:
Human Polyclonal APOL1 Primary Antibody for IHC, IHC (p) - ABIN4281231
Madhavan, OToole, Konieczkowski, Ganesan, Bruggeman, Sedor: APOL1 localization in normal kidney and nondiabetic kidney disease. in Journal of the American Society of Nephrology : JASN 2011
Show all 2 Pubmed References
Human Monoclonal APOL1 Primary Antibody for ELISA, WB - ABIN968963
Vanhollebeke, Nielsen, Watanabe, Truc, Vanhamme, Nakajima, Moestrup, Pays: Distinct roles of haptoglobin-related protein and apolipoprotein L-I in trypanolysis by human serum. in Proceedings of the National Academy of Sciences of the United States of America 2007
Show all 2 Pubmed References
Human Polyclonal APOL1 Primary Antibody for ELISA, WB - ABIN449525
Pérez-Morga, Vanhollebeke, Paturiaux-Hanocq, Nolan, Lins, Homblé, Vanhamme, Tebabi, Pays, Poelvoorde, Jacquet, Brasseur, Pays: Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. in Science (New York, N.Y.) 2005
zApoL1 is essential for proper blood filtration in the zebrafish glomerulus and that zApoL1 affects the expression of nephrin (show NPHS1 Antibodies)
Divergent intracellular biological pathways of ancestral and variant APOL1 may explain a worsened prognosis as demonstrated in Systemic Lupus Erythematosus.
Roles of APOL1 G1 and G2 variants in sickle cell disease patients: kidney is the main target.
Two APOL1 renal-risk variants are associated with longer dialysis survival in African Americans with non-diabetic end-stage renal disease.
The frequency of APOL1 risk variants ranged from 7.0% to 11.0%.
The synergy of circulating factor suPAR and APOL1 G1 or G2 on alphavbeta3 integrin activation is a mechanism for CKD.
Among African Americans with hypertension-attributed chronic kidney disease, APOL1 risk variants were not associated with an overall risk for cardiovascular disease although some signals for cardiovascular mortality were noted.
The proteomic profile of apoL1 is modified in HDLs (show CSF1R Antibodies) of high cardiovascular risk patients, and apoL1 plasma levels are significantly lower in serum and in HDL3 of patients that will suffer an adverse cardiac event within 3 years.
Relationships between APOL1 kidney risk variants and cardiovascular disease (CVD) susceptibility and CVD-related death remain controversial. Some studies detected an increased risk for CVD, whereas others support protection from death and subclinical CVD and cerebrovascular disease
mice with podocyte-specific expression of either APOL1 risk allele (G1 or G2), but not of the G0 allele, develop functional (albuminuria and azotemia), structural (foot-process effacement and glomerulosclerosis) and molecular (gene-expression) changes that closely resemble human kidney disease. Expression of the risk-variant APOL1 alleles interferes with endosomal trafficking and blocks autophagic flux.
APOL1 single nucleotide polymorphisms are associated with nephropathy.
This gene encodes a secreted high density lipoprotein which binds to apolipoprotein A-I. Apolipoprotein A-I is a relatively abundant plasma protein and is the major apoprotein of HDL. It is involved in the formation of most cholesteryl esters in plasma and also promotes efflux of cholesterol from cells. This apolipoprotein L family member may play a role in lipid exchange and transport throughout the body, as well as in reverse cholesterol transport from peripheral cells to the liver. Several different transcript variants encoding different isoforms have been found for this gene.